This is an AMP page which is for mobile devices.
Link your Twitter Account to Market Wire News
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
home / articles / AKRO - Why Is Liver Disease Focused Akero Therapeutics Stock Sinking Today? | Benzinga
Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH).
Efruxifermin was not statistically significant in topping the placebo in improving liver scarring without worsening of NASH, resulting in shares tumbling.
A trend was observed for ...
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by Benzinga via Quote Media. Read our full disclaimer.